|
|
|
|
|
|
|
|
Ron Waldorf, CEO AcuNetx
and
Co-Presenter, Sgt. Richard Studdard (LAPD ret.)
will present
AUTOMATED COLLECTION OF EYE SIGNS OF DRUG IMPAIRMENT
IN THE DRIVING AND INDUSTRIAL SETTINGS
on Nov 5 - 6, 2007
at California Association of Toxicologists conference
in Seaside, CA
Torrance, California, October 8, 2007
TORRANCE, CA -- 10/08/2007 -- AcuNetx, Inc. (OTCBB: ANTX), a
medical device company, announced today that its CEO, Ron Waldorf, and Sgt. Richard Studdard (LAPD ret.) will present
a paper entitled 'AUTOMATED COLLECTION OF EYE SIGNS OF DRUG IMPAIRMENT IN THE DRIVING AND INDUSTRIAL SETTINGS'
at the California Association of Toxicologies conference on November 5 - 6, 2007.
About AcuNetx, Inc.
AcuNetx markets a diverse line of diagnostic, analytical and therapeutic
tools to audiologist, neurologists, otolaryngologists and physical
therapists as well as hospitals, clinics, and extended care facilities. The
company's subsidiaries are focused on bone growth and worker impairment
products and services. AcuNetx is headquartered in Torrance, CA. For more
information concerning AcuNetx and its subsidiaries, please visit
www.acunetx.com
FOR FURTHER INFORMATION CONTACT:
Name: J. Astor
G.M. Astor & Associates
Telephone: 818 788 4346
gastor@acunetx.com
Safe Harbor for Forward-Looking Statements
This news release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. While these statements are made to convey to the public the
company’s progress, business opportunities and growth prospects, readers are
cautioned that such forward-looking statements represent management’s
opinion. Whereas management believes such representations to be true and
accurate based on information and data available to the company at this
time, actual results may differ materially from those described. The
company’s operations and business prospects are always subject to risk and
uncertainties. Important factors that may cause actual results to differ are
set forth in the company’s periodic filings with the U.S. Securities and
Exchange Commission.
|
|
|
|